Small molecule inhibitors like MI-2, MI-3, MI-525, and MI-503, designed to disrupt the menin-MLL1 interaction, offer potential therapeutic avenues for MLL-r leukemia [15]. The gene discussed is KMT2A; the disease is leukemia.